



Cerebral amyloid angiopathy associated with Alzheimer's Disease: two pathologies from a single peptide?

Gabriele Gaggero¹ , Davide Taietti² , Veronica Parrella³, Pietro Fiaschi⁴ 

¹Pathology Unit, IRCCS Istituto Giannina Gaslini, Genoa, Italy

²Pathology Unit, ASST Fatebenefratelli-Sacco, Milan, Italy

³Department of Integrated Surgical and Diagnostic Sciences (DISC), Division of Anatomical Pathology, Scuola di Scienze Mediche e Farmaceutiche, Università di Genova, Genoa, Italy

⁴Department of Neurosciences, Rehabilitation, Ophthalmology, Genetics, Maternal and Child Health (DINOEMI), Università di Genova, Genoa, Italy

Keywords: amyloid, brain, angiopathy, Alzheimer's Disease

To the Editors

We read with interest the extensive and thorough ahead-of-print review article entitled 'Updates on pharmacological treatment for Alzheimer's Disease' [1]. This article addresses the compelling issue — not only medical/scientific, but also social and cost/benefit — of pharmacological therapies to slow/block the progressive organisation of β -amyloid peptide ($A\beta$) deposits in Alzheimer's Disease (AD), their specific molecular targets, and the major related phase III and IV clinical trials.

One aspect that is not addressed is the frequent coexistence of AD and other β -amyloid deposition pathologies, which could, at least hypothetically, benefit equally from the aforementioned anti-amyloid therapies.

Below, we briefly report a histological case arising in this context.

A 78-year-old woman presented with new-onset dementia and sudden loss of left-side motor skills. Radiology showed a haemorrhage with marked signal reduction in the right parietal lobe, with contrast enhancement of uncertain significance, whether inflammatory or neoplastic: for this reason, surgery was performed.

Microscopy revealed thickened and hyalinised vessels (Fig. 1a) that were positive for Congo red histological staining (Fig. 1b) and $A\beta$ immunohistochemical staining (Fig. 1c),

leading to the diagnosis of cerebral amyloid angiopathy (CAA). The surrounding tissue also showed microbleeds (Fig. 2a) and scattered so-called 'red motor neurons' (Fig. 2b), which are hypoxic consequences of CAA [2], and were likely to be the cause of the clinically observed motor impairment. However, the aforementioned $A\beta$ immunohistochemistry also highlighted coexisting microscopic AD morphology with typical extravascular deposits, both diffuse and focal (Fig. 1c), justifying the neurological condition of dementia.

The accumulation of $A\beta$ in the brain can lead to several diseases, including CAA and AD. Whereas in CAA $A\beta$ is deposited in the vascular wall, in AD it accumulates at the extravascular parenchymal level or intracytoplasmically in neurons in the form of tangles. These different $A\beta$ depositions would be the result of different pathways, but with common initial steps, which is why the two diseases often co-occur [3, 4]. It is estimated that c.48% of AD cases have co-existing CAA [5].

The coexistence of CAA and AD is often suspected clinically, and the fact that it can be documented histologically supports this thesis, as well as that of a common aetiopathogenesis. However, despite the existence of important data [2–5], it is still not fully understood why some individuals develop only CAA, some others only AD, and in still others, as in the present case, both CAA and AD coexist.

Address for correspondence: Gabriele Gaggero MD, Pathology Unit, IRCCS Istituto Giannina Gaslini, Genoa, Italy; e-mail: gabriele.gaggero@outlook.it

Received: 21.10.2023 Accepted: 08.11.2023 Early publication date: 19.12.2023

This article is available in open access under Creative Commons Attribution-Non-Commercial-No Derivatives 4.0 International (CC BY-NC-ND 4.0) license, allowing to download articles and share them with others as long as they credit the authors and the publisher, but without permission to change them in any way or use them commercially.




Figure 1. Photomicrographs of cerebral tissue with amyloid angiopathy (CAA): (a) view of an intraparenchymal blood vessel with hyaline wall thickening (arrow) suspicious for amyloid deposition (haematoxylin and eosin, 10×); (b) Congo red staining showing pink amyloid deposition (arrow, 20×); (c) β -amyloid immunohistochemistry showing Alzheimer’s Disease deposits: besides confirmed positivity in vessel wall (white arrow), further multiple intraparenchymal/extravascular positivities are highlighted, both in focal/targetoid form (black arrows) and as diffuse deposits (black arrowheads, 10×)




Figure 2. Photomicrographs of surrounding brain tissue: (a) intraparenchymal microbleeds (white arrows) (haematoxylin and eosin, 4×); (b) so-called ‘red neurons’ (black arrow), a morphological feature of neuronal hypoxic distress CAA-related (haematoxylin and eosin, 40×)

The case described does not represent a novelty of A β deposition brain lesions, but it helps to reflect, also in a histological/topographical sense, that the consideration of anti-amyloid therapies should be placed in a broader context than AD, although AD is certainly its most important chapter in terms of incidence, prevalence, morbidity, mortality, and cost to society.

Article information

Authors' contributions: *conceptualisation: GG, DT, VP, PF; literature search: GG, DT; writing — original draft preparation: GG, DT; writing — review and editing: VP, PF; visualisation: DT; supervision: PF. All authors have read and agreed to the published version of the manuscript.*

Conflicts of interest: *None.*

Funding: *None.*

References

1. Tipton PW. Updates on pharmacological treatment for Alzheimer's disease. *Neurol Neurochir Pol.* 2023 [Epub ahead of print], doi: [10.5603/pjnns.96286](https://doi.org/10.5603/pjnns.96286), indexed in Pubmed: [37606550](https://pubmed.ncbi.nlm.nih.gov/37606550/).
2. Smith EE. Cerebral amyloid angiopathy as a cause of neurodegeneration. *J Neurochem.* 2018; 144(5): 651–658, doi: [10.1111/jnc.14157](https://doi.org/10.1111/jnc.14157), indexed in Pubmed: [28833176](https://pubmed.ncbi.nlm.nih.gov/28833176/).
3. Greenberg SM, Bacskai BJ, Hernandez-Guillamon M, et al. Cerebral amyloid angiopathy and Alzheimer disease - one peptide, two pathways. *Nat Rev Neurol.* 2020; 16(1): 30–42, doi: [10.1038/s41582-019-0281-2](https://doi.org/10.1038/s41582-019-0281-2), indexed in Pubmed: [31827267](https://pubmed.ncbi.nlm.nih.gov/31827267/).
4. Ghiso J, Tomidokoro Y, Revesz T, et al. Cerebral amyloid angiopathy and alzheimer's disease. *Hirosaki Igaku.* 2010; 61 (Suppl): S111–S124, indexed in Pubmed: [21037967](https://pubmed.ncbi.nlm.nih.gov/21037967/).
5. Jäkel L, De Kort AM, Klijn CJM, et al. Prevalence of cerebral amyloid angiopathy: A systematic review and meta-analysis. *Alzheimers Dement.* 2022; 18(1): 10–28, doi: [10.1002/alz.12366](https://doi.org/10.1002/alz.12366), indexed in Pubmed: [34057813](https://pubmed.ncbi.nlm.nih.gov/34057813/).